Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Marta Martin-Richard
Based on 2 articles published since 2008
||||

Between 2008 and 2019, Marta Martín-Richard wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Guideline [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. 2016

Martin-Richard, Marta / Ginès, Angels / Ayuso, Juan Ramón / Sabater, Luis / Fabregat, Joan / Mendez, Ramiro / Fernández-Esparrach, Glòria / Molero, Xavier / Vaquero, Eva C / Cuatrecasas, Miriam / Ferrández, Antonio / Maurel, Joan / Anonymous3560884. ·Servicio de Oncología Médica, Hospital Sant Pau, Barcelona, España. Electronic address: mmartinri@santpau.cat. · Servicio de Gastroenterología, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Radiología, Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Cirugía, Hospital Clínico Universitario de Valencia, Valencia, España. · Servicio de Cirugía, Hospital de Bellvitge, Barcelona, España. · Servicio de Radiología, Hospital Clínico San Carlos, Madrid, España. · Servicio de Gastroenterología, Hospital Vall d'Hebron, Barcelona, España. · Servicio de Anatomía Patológica, Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Anatomía Patológica, Hospital Clínico Universitario de Valencia, Valencia, España. · Servicio de Oncología Médica, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, España; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, España. ·Med Clin (Barc) · Pubmed #27726847.

ABSTRACT: BACKGROUND AND OBJECTIVE: Clinical management of adenocarcinoma of the pancreas is complex, and requires a multidisciplinary approach. The same applies for the premalignant lesions that are increasingly being diagnosed. The current document is an update on the diagnosis and management of premalignant lesions and adenocarcinoma of the pancreas. PATIENTS AND METHODS: A conference to establish the basis of the literature review and manuscript redaction was organized by the Grupo Español Multidisciplinar en Cáncer Digestivo. Experts in the field from different specialties (Gastroenterology, Surgery, Radiology, Pathology, Medical Oncology and Radiation Oncology) met to prepare the present document. RESULTS: The current literature was reviewed and discussed, with subsequent deliberation on the evidence. CONCLUSIONS: Final recommendations were established in view of all the above.

2 Article SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients. 2017

Arqueros, Cristina / Salazar, Juliana / Arranz, M J / Sebio, Ana / Mora, Josefina / Sullivan, Ivana / Tobeña, María / Martín-Richard, Marta / Barnadas, Agustí / Baiget, Montserrat / Páez, David. ·Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/Sant Quintí, 89, 08026, Barcelona, Spain. · Department of Genetics, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. · CIBERER U-705, Barcelona, Spain. · Fundació Docència i Recerca Mútua Terrassa, Terrassa, Spain. · Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. · Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/Sant Quintí, 89, 08026, Barcelona, Spain. dpaez@santpau.cat. ·Med Oncol · Pubmed #28687963.

ABSTRACT: Secreted protein acidic and rich in cysteine (SPARC) is a glycoprotein of the extracellular matrix whose expression can be altered in malignant pancreatic cells and in the adjacent stromal fibroblasts. We evaluated the possible role of SPARC gene variants as prognostic markers for locally advanced and metastatic pancreatic cancer. We analyzed eight tagging single-nucleotide polymorphisms (TagSNPs) in the SPARC gene in 74 patients with pancreatic ductal adenocarcinoma treated with chemotherapy alone or combined with radiotherapy. TagSNPs were chosen using the HapMap genome browser and Haploview software 4.2 based on two predefined criteria: (1) coefficient cutoff of 0.80 and (2) minor allele frequency (MAF) ≥ 0.10. Univariate analyses revealed significant associations between four SNPs (rs17718347, rs2347128, rs3210714, and rs967527) and PFS. The rs3210714 genetic variant was also associated with OS. In the multivariate analyses, rs17718347 (HR 0.4; 95% CI 0.2-0.8; p = 0.013) and rs2347128 (HR 0.5; 95% CI 0.3-0.9; p = 0.049) remained statistically associated with PFS. In addition, patients harboring the T-A-G haplotype (rs17718347, rs1978707, rs2347128) had a better PFS (p = 0.002). Our findings suggest that SPARC polymorphisms may be useful in predicting outcome in patients with locally advanced and metastatic pancreatic cancer.